Close

Cytosorbents (CTSO) Awarded $4.3M Contract by the U.S. DoD to Develop HemoDefend-BGA

Go back to Cytosorbents (CTSO) Awarded $4.3M Contract by the U.S. DoD to Develop HemoDefend-BGA

CytoSorbents Awarded an Approximately $4.3M Contract by the U.S. Department of Defense to Develop HemoDefend-BGA™ for Freeze-Dried Universal Plasma

October 6, 2022 7:00 AM EDT

PRINCETON, N.J., Oct. 6, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader specializing in blood purification, announced today that the U.S. Army Medical Research Acquisition Activity (USAMRAA) has awarded the Company a three-year Phase III contract valued at $4,292,641 to customize the design of the HemoDefend-BGA filter for sterile integration into collections systems for freeze-dried plasma processing to generate freeze-dried universal plasma.  Without the need for blood typing,... More